Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jelic, S.
Right arrow Articles by Le Jemtel, T. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jelic, S.
Right arrow Articles by Le Jemtel, T. H.
(Chest. 2006;130:1220-1230.)
© 2006 American College of Chest Physicians

Diagnostic Usefulness of B-Type Natriuretic Peptide and Functional Consequences of Muscle Alterations in COPD and Chronic Heart Failure*

Sanja Jelic, MD and Thierry H. Le Jemtel, MD

* From the Division of Pulmonary, Allergy, and Critical Care Medicine (Dr. Jelic), Columbia University College of Physicians and Surgeons, New York, NY; and Division of Cardiology (Dr. Le Jemtel), Tulane University, New Orleans, LA.

Correspondence to: Sanjo Jelic, MD, Columbia University College of Physicians and Surgeons, PH 8, Room 840, 630 West 168th St, New York, NY 10032; e-mail: sj366{at}columbia.edu

Abstract

COPD affects up to one third of patients with chronic heart failure. The coexistence of COPD and chronic heart failure presents clinicians with diagnostic and therapeutic challenges. Measurement of B-type natriuretic peptide plasma levels facilitates the diagnosis of acute dyspnea in patients known to have both COPD and chronic heart failure. Patients with COPD or chronic heart failure have skeletal muscle abnormalities that limit functional capacity independently from primary organ failure. Exercise training reverses skeletal muscle abnormalities in patients with COPD or chronic heart failure and may be particularly indicated in patients with coexistent COPD and chronic heart failure.

Key Words: B-type natriuretic peptide • chronic heart failure • COPD • exercise training • skeletal muscle abnormalities






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American College of Chest Physicians.